NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Bank of India FY26 Net Profit Rises 14% to ₹10,527 Cr; Asset Quality Improves Significantly
Bank of India reported a resilient performance for FY26, with net profit growing 14% YoY to ₹10,527 crore. Asset quality showed marked improvement as Gross NPA fell to 1.98% and Net NPA reached 0.56%, supported by a low slippage ratio of 0.83%. The bank maintains a strong capital position with a CRAR of 18.01%, well above regulatory requirements. Management has guided for a 15-16% growth in advances for FY27, focusing on high-yielding RAM segments and retail deposit accretion.
முக்கிய அம்சங்கள்
Net Profit increased 14% YoY to ₹10,527 crore for FY26, with Q4 profit up 15% at ₹3,016 crore.Asset quality improved significantly with Gross NPA at 1.98% (down 129 bps) and Net NPA at 0.56% (down 26 bps).Global Gross Advances grew 15.82% YoY to ₹7.71 lakh crore, led by a 19.11% growth in RAM advances.Capital Adequacy Ratio (CRAR) strengthened to 18.01%, providing a substantial cushion for future growth and ECL transitions.Management expects to fund ₹10,000-12,000 crore under the new ECLGS 5.0 scheme for MSMEs and corporates.
👀 கவனிக்க வேண்டியவை
Investors should view the improving asset quality and strong capital buffer as positive indicators for long-term stability. The bank's focus on RAM advances and digital initiatives suggests a strategy geared towards higher margins and operational efficiency.
Mankind Pharma Reaffirmed [ICRA]AA+ (Stable) Rating for ₹5,000 Crore NCDs
ICRA Limited has reaffirmed the credit ratings for Mankind Pharma Limited, maintaining a high-grade [ICRA]AA+ (Stable) for its ₹5,000 crore Non-convertible Debentures. The rating agency also reaffirmed the [ICRA]AA+ (Stable) and [ICRA]A1+ ratings for ₹1,250 crore in fund-based limits. Furthermore, a new [ICRA]A1+ rating was assigned to the company's ₹600 crore Commercial Paper program. These ratings reflect the company's robust financial profile and strong creditworthiness in the pharmaceutical sector.
முக்கிய அம்சங்கள்
ICRA reaffirmed [ICRA]AA+ (Stable) rating for ₹5,000 crore Non-convertible DebenturesReaffirmed [ICRA]AA+ (Stable) and [ICRA]A1+ for ₹1,250 crore fund-based limitsAssigned a new [ICRA]A1+ rating for ₹600 crore Commercial PaperTotal rated debt instruments and limits amount to ₹6,850 crore
👀 கவனிக்க வேண்டியவை
Investors should take confidence in the company's high credit rating, which indicates a strong ability to meet financial obligations and access capital at competitive rates. No immediate action is required as the ratings remain stable.
D-Link India FY26 Revenue Up 13%, Announces Total Dividend of ₹27.50 Per Share
D-Link (India) Limited reported a 13.2% growth in annual revenue to ₹1,559 crore for FY26, although net profit remained flat at ₹102.9 crore. The Board has recommended a significant total dividend of ₹27.50 per share, which includes a ₹20 final dividend and a ₹7.50 special dividend. While top-line growth is healthy, the company faced margin pressure as profit before tax grew only marginally to ₹138.5 crore. Additionally, the company is strengthening its board with the proposed appointment of Ms. Della Chang as an Independent Director.
முக்கிய அம்சங்கள்
Annual revenue from operations grew 13.2% YoY to ₹1,55,901.66 Lakhs from ₹1,37,716.42 Lakhs.Recommended a total dividend of ₹27.50 per share (₹20 final + ₹7.50 special) for FY26.Net profit for the full year remained stable at ₹10,294.98 Lakhs compared to ₹10,305.29 Lakhs in FY25.Earnings Per Share (EPS) for FY26 stood at ₹29.00, nearly identical to the previous year's ₹29.03.Record date for dividend entitlement is fixed as July 10, 2026, with the AGM scheduled for August 10, 2026.
👀 கவனிக்க வேண்டியவை
Investors should find the high dividend payout attractive, offering a strong yield at current price levels. However, the flat profit growth despite rising revenues suggests a need to monitor operating margins and cost management in the coming fiscal year.
D-Link India Recommends ₹27.50 Total Dividend; Sets Record Date for July 10, 2026
D-Link (India) Limited's Board has recommended a total dividend of ₹27.50 per equity share for FY26, consisting of a final dividend of ₹20.00 and a special dividend of ₹7.50. The company has fixed Friday, July 10, 2026, as the record date to determine shareholder eligibility. On the financial front, standalone revenue for FY26 grew to ₹1,55,901.66 lakhs from ₹1,37,716.42 lakhs in FY25. Standalone net profit for the full year remained stable at ₹10,294.98 lakhs compared to ₹10,305.29 lakhs in the previous fiscal year.
முக்கிய அம்சங்கள்
Recommended a total dividend of ₹27.50 per equity share (₹20 final and ₹7.50 special dividend) on a face value of ₹2.Fixed Friday, July 10, 2026, as the Record Date for dividend entitlement.FY26 standalone revenue from operations increased by 13.2% year-on-year to ₹1,55,901.66 lakhs.FY26 standalone net profit stood flat at ₹10,294.98 lakhs against ₹10,305.29 lakhs in FY25.Full-year basic and diluted Earnings Per Share (EPS) stood at ₹29.00 for FY26.
👀 கவனிக்க வேண்டியவை
Investors seeking strong dividend yields should ensure they hold D-Link India shares before the ex-dividend date relative to the July 10, 2026 record date. The substantial special dividend reflects strong cash generation despite flat net profit growth.
Bank of India Sets May 29, 2026, as Record Date for Dividend Eligibility
Bank of India has announced that its 30th Annual General Meeting (AGM) will be held on June 15, 2026. The bank has fixed May 29, 2026, as the record date to determine the eligibility of shareholders for the payment of dividends. If the dividend is approved by shareholders at the AGM, it will be paid to those whose names appear in the Register of Members as of the close of business on the record date. Additionally, the bank will dispatch the Annual Report to shareholders whose emails are registered by May 22, 2026.
முக்கிய அம்சங்கள்
Record date for dividend eligibility is fixed as Friday, May 29, 202630th Annual General Meeting (AGM) scheduled for Monday, June 15, 2026Dividend payment is subject to shareholder approval at the upcoming AGMCut-off date for dispatch of Annual Report and AGM notice is May 22, 2026The AGM will be conducted via Video Conferencing or Other Audio-Visual Means
👀 கவனிக்க வேண்டியவை
Investors interested in receiving the dividend should ensure they hold the bank's shares before the ex-dividend date, which typically precedes the May 29 record date. Existing shareholders should verify their email addresses with the RTA by May 22 to receive the Annual Report.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Bank of India Recommends ₹4.65 Dividend; FY26 Net Profit Rises to ₹10,527 Crore
Bank of India has recommended a final dividend of ₹4.65 per equity share for FY2025-26, representing 46.50% of the face value. The bank reported a strong standalone net profit of ₹10,527.15 crore for the full year, a 14.2% increase over the previous fiscal. Asset quality improved significantly with Gross NPA dropping to 1.98% from 3.27% YoY. The bank maintains a healthy Capital Adequacy Ratio of 18.01%, indicating a robust balance sheet.
முக்கிய அம்சங்கள்
Recommended final dividend of ₹4.65 per equity share with a record date of May 29, 2026.FY26 Standalone Net Profit grew to ₹10,527.15 crore from ₹9,219.02 crore in FY25.Gross NPA reduced to 1.98% (₹15,306 crore) from 3.27% (₹21,749 crore) year-on-year.Net NPA improved to 0.56% compared to 0.82% in the previous year.Capital Adequacy Ratio (Basel III) stands strong at 18.01% with CET 1 at 15.05%.
👀 கவனிக்க வேண்டியவை
Investors seeking dividend income should ensure they hold shares by the May 29 record date. The bank's sharp reduction in NPAs and steady profit growth suggest improving fundamental strength.
Bank of India Board Approves Raising Rs 7,500 Crore via Basel-III Bonds
The Board of Directors of Bank of India has approved a significant capital raising plan of up to Rs 7,500 crore for the financial year 2026-27. This fundraise will be conducted through the issuance of Basel-III compliant bonds to bolster the bank's capital adequacy. The total amount is split between Rs 2,500 crore in Tier-I bonds and Rs 5,000 crore in Tier-II bonds. This move is intended to support the bank's growth trajectory and meet regulatory capital requirements.
முக்கிய அம்சங்கள்
Approved total capital raising of up to Rs 7,500 crore for FY 2026-27Issuance of Basel-III compliant Tier-I bonds amounting to Rs 2,500 croreIssuance of Basel-III compliant Tier-II bonds amounting to Rs 5,000 croreThe board meeting was held and concluded on April 30, 2026
👀 கவனிக்க வேண்டியவை
Investors should monitor the bank's capital adequacy ratio improvements following the issuance. This fundraise is a positive signal for the bank's ability to expand its loan book in the coming fiscal year.
Bank of India MD & CEO Rajneesh Karnatak's Term Extended for 3 Years
The Central Government has approved the extension of Shri Rajneesh Karnatak's tenure as the Managing Director and Chief Executive Officer of Bank of India. His current term was scheduled to conclude on April 28, 2026. The extension is granted for a period of three years beyond his current term or until further orders. This move ensures leadership continuity at the public sector bank, which is typically viewed as a positive sign for strategic stability.
முக்கிய அம்சங்கள்
Extension of Shri Rajneesh Karnatak's term as MD & CEO for a period of 3 yearsCurrent term was set to end on April 28, 2026Notification issued by the Central Government on April 23, 2026Extension granted under the Banking Companies (Acquisition and Transfer of Undertakings) Act, 1970
👀 கவனிக்க வேண்டியவை
Investors should welcome the leadership continuity as it reduces transition risks. Maintain a positive outlook on the stock while monitoring upcoming quarterly results for consistent operational performance.
Mankind Pharma Assigned CARE AA+; Stable Rating for ₹1,000 Crore Bank Facilities
Mankind Pharma Limited has received new credit ratings from CARE Ratings Limited for its bank facilities totaling ₹1,000 crore. The agency assigned a 'CARE AA+; Stable' rating for long-term facilities and 'CARE A1+' for short-term facilities. These high investment-grade ratings underscore the company's robust credit profile and strong liquidity position. Such ratings typically allow the company to access capital at competitive interest rates and reflect a low risk of default.
முக்கிய அம்சங்கள்
CARE Ratings assigned 'CARE AA+; Stable' for long-term bank facilities.Short-term bank facilities were assigned the highest possible rating of 'CARE A1+'.The total value of the bank facilities covered under this rating assignment is ₹1,000 crore.The ratings were assigned at the request of the company to assess its creditworthiness.
👀 கவனிக்க வேண்டியவை
The high credit rating confirms Mankind Pharma's financial stability and strong balance sheet. Investors should view this as a positive indicator of the company's ability to manage debt and fund future growth at optimal costs.
Bank of India Q4 FY26 Provisional: Global Business Grows 14.5% YoY to ₹16.98 Lakh Cr
Bank of India reported strong provisional growth for the fiscal year ending March 31, 2026, with total global business reaching ₹16.98 lakh crore. Global advances grew by 15.69% YoY, significantly outperforming global deposit growth of 13.58% YoY. A key driver was the domestic RAM (Retail, Agri, MSME) segment, which surged by 18.63% YoY to ₹3.83 lakh crore. These figures indicate robust credit demand and healthy balance sheet expansion for the public sector lender.
முக்கிய அம்சங்கள்
Global Business increased 14.53% YoY to ₹16,98,026 crore as of March 31, 2026Gross Advances (Global) rose 15.69% YoY to ₹7,70,566 crore, showing strong credit momentumDomestic RAM Advances grew significantly by 18.63% YoY to ₹3,82,796 croreGlobal Deposits stood at ₹9,27,460 crore, marking a 13.58% YoY growthDomestic Gross Advances grew 15.95% YoY to ₹6,53,441 crore
👀 கவனிக்க வேண்டியவை
The strong growth in high-yield RAM advances and overall credit suggests improving profitability; investors should monitor the upcoming full results for Net Interest Margin (NIM) and asset quality trends.
JNK India Bags Major Order Worth ₹300-600 Crore for Refinery Project
JNK India Limited has secured a 'Major' order from its promoter entity, JNK Global Co., Ltd., Korea. The contract involves providing support services and supplies for a Cracker Furnace Package for a refinery project located in India. Valued between ₹300 crore and ₹600 crore, this order significantly boosts the company's order book. The project is slated for completion by February 2, 2028, ensuring long-term revenue visibility.
முக்கிய அம்சங்கள்
Order value classified as 'Major', ranging between ₹300 crore and ₹600 croreContract awarded by promoter JNK Global Co., Ltd., Korea, for a domestic refinery projectProject execution timeline set for completion by February 2, 2028Transaction confirmed as a related party contract conducted at an arm's length basis
👀 கவனிக்க வேண்டியவை
This order win provides strong revenue visibility for the next two fiscal years; investors should monitor execution milestones and potential margin impacts from this related-party transaction.
Mankind Pharma Acquires Roche's Rivotril Brand to Strengthen CNS Portfolio in India
Mankind Pharma has acquired the exclusive rights to manufacture, market, and distribute the innovator brand Rivotril (clonazepam) from Roche for the Indian market. This acquisition is a strategic move to bolster Mankind's presence in the Central Nervous System (CNS) and chronic therapy segments, which are high-growth areas. The company plans to leverage its massive distribution network of over 17,700 professionals and reach of 5 lakh doctors to scale the brand. This deal follows Mankind's recent focus on specialty segments and high-margin chronic therapies to diversify its portfolio.
முக்கிய அம்சங்கள்
Acquired exclusive rights for the innovator brand Rivotril from Roche for the Indian marketStrengthens strategic focus on chronic therapies and the Central Nervous System (CNS) segmentLeverages a distribution network of 17,700+ professionals and 32 manufacturing facilitiesAims to utilize a reach of over 5 lakh doctors to drive penetration in urban and semi-urban marketsCreates a platform for future expansion through potential line extensions in the CNS category
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive development as it enhances Mankind's portfolio with a high-recall innovator brand in the chronic segment. Monitor the company's execution in scaling this brand and its impact on overall margins in the coming quarters.
JNK India Appoints Anand Agarwal as Interim CFO and Key Managerial Personnel
JNK India Limited has appointed Mr. Anand Agarwal as its Interim Chief Financial Officer and Key Managerial Personnel, effective March 12, 2026. Mr. Agarwal is a Chartered Accountant with 20 years of experience in finance leadership across the EPC, infrastructure, and oil & gas sectors. He will hold the position until a permanent CFO is appointed by the Board. This move ensures continuity in the company's financial governance and regulatory compliance following the board meeting held on March 12, 2026.
முக்கிய அம்சங்கள்
Mr. Anand Agarwal appointed as Interim CFO and KMP effective March 12, 2026.Brings 20 years of experience from senior roles at companies like Kalpataru Projects International Limited.Expertise includes project finance, treasury, debt structuring, and ERP transformation.Authorized by the Board to determine materiality of events for SEBI disclosures.The appointment follows a Board Meeting concluded within 26 minutes on March 12, 2026.
👀 கவனிக்க வேண்டியவை
Investors should view this as a routine management transition and monitor for the announcement of a permanent CFO appointment. The interim choice appears well-qualified with significant industry experience, suggesting minimal disruption to financial operations.
Fitch Upgrades Bank of India's Viability Rating to 'bb'; Affirms IDR at 'BBB-'
Fitch Ratings has upgraded Bank of India's (BOI) Viability Rating (VR) to 'bb' from 'bb-', signaling a stronger intrinsic financial profile. The bank's Long-Term Issuer Default Rating (IDR) remains affirmed at 'BBB-' with a Stable Outlook, reflecting high expectations of government support. Key financial metrics have shown marked improvement, with the impaired-loan ratio dropping to 2.3% in 9MFY26 and credit costs reducing to 0.4%. The bank maintains a healthy capital cushion with a CET1 ratio of 15.3%, well above regulatory requirements.
முக்கிய அம்சங்கள்
Viability Rating (VR) upgraded to 'bb' from 'bb-' reflecting improved risk profile and asset quality.Impaired-loan ratio improved significantly to 2.3% in 9MFY26 from 3.3% in the previous year.Common Equity Tier 1 (CET1) ratio strengthened to 15.3%, providing a 400bp cushion over the rating threshold.Credit costs declined to 0.4% of loans in 9MFY26, down from 1.0% in FY25.Fitch affirmed the Long-Term Issuer Default Rating at 'BBB-' with a Stable Outlook.
👀 கவனிக்க வேண்டியவை
The upgrade in the Viability Rating confirms the bank's improving fundamental health and better risk management. Investors should monitor if the bank can sustain these asset quality improvements while managing loan growth in a competitive environment.
Mankind Pharma Credit Ratings Reaffirmed by ICRA for ₹6,250 Crore Debt Instruments
ICRA Limited has reaffirmed the credit ratings for Mankind Pharma's debt instruments totaling ₹6,250 crore. The Non-Convertible Debentures (NCDs) worth ₹5,000 crore maintained an [ICRA]AA+/Stable rating. Additionally, long-term and short-term fund-based limits of ₹1,250 crore were reaffirmed at [ICRA]AA+ (Stable) and [ICRA]A1+ respectively. This reaffirmation reflects the company's strong financial profile and continued creditworthiness in the pharmaceutical sector.
முக்கிய அம்சங்கள்
ICRA reaffirmed [ICRA]AA+/Stable rating for ₹5,000 crore Non-Convertible Debentures.Fund-based limits of ₹1,250 crore reaffirmed at [ICRA]AA+ (Stable) and [ICRA]A1+.Total debt instruments covered under this rating action amount to ₹6,250 crore.The 'Stable' outlook indicates ICRA's expectation of consistent performance and credit metrics.
👀 கவனிக்க வேண்டியவை
The reaffirmation of high credit ratings confirms the company's strong balance sheet and low default risk. Investors should view this as a validation of financial stability, requiring no immediate portfolio changes.
Bank of India to Exercise Call Option on 9.30% AT1 Bonds Series VII
Bank of India has announced its decision to exercise the call option for its 9.30% Additional Tier I (AT1) Bonds Series VII. The bank has fixed March 13, 2026, as the record date to identify bondholders eligible for the redemption. The total payment, comprising the principal amount and interest for the broken period, will be disbursed on March 30, 2026. This move is a standard capital management procedure for bonds issued in March 2021 and indicates the bank's stable liquidity position.
முக்கிய அம்சங்கள்
Exercise of call option for 9.30% Additional Tier I Bonds Series VII (ISIN: INE084A08144)Record date for determining eligible bondholders is March 13, 2026Full redemption of principal and interest scheduled for March 30, 2026Bonds were originally issued on March 30, 2021, with a 5-year call option clause
👀 கவனிக்க வேண்டியவை
Bondholders should ensure their bank and demat details are updated by March 13, 2026, to receive the redemption proceeds. Equity investors can view this as a routine capital management activity reflecting healthy liquidity.
JNK India Q3 FY26 PAT Surges 534% YoY to ₹180.2 Mn; Revenue Doubles to ₹2,062 Mn
JNK India reported a stellar Q3 FY26 with revenue growing 112.8% YoY to ₹2,062.3 million and PAT jumping 534.1% to ₹180.2 million. The company maintains a robust order book of approximately ₹1,700 crores, supported by domestic projects like BPCL Bina and international prospects like the Dangote refinery expansion. The newly formed JV with Chemdist contributed ₹23 crores in revenue this quarter, signaling progress in green hydrogen and sustainable fuels. Management highlighted a shift in accounting policy to the input method, which is expected to normalize margins moving forward.
முக்கிய அம்சங்கள்
Revenue grew 112.8% YoY to ₹2,062.3 million with an operating profit margin of 27.2%Net profit (PAT) witnessed a massive 534.1% YoY increase to ₹180.2 millionOrder book remains strong at approximately ₹1,700 crores as of January 1, 2026Subsidiary business (Chemdist JV) contributed ₹23 crores to revenue with a ₹100 crore order bookManagement identified significant future opportunities in Nigeria (Dangote refinery) and the Middle East
👀 கவனிக்க வேண்டியவை
Investors should view the strong revenue growth and healthy order pipeline as a positive sign of execution capability. Monitor the conversion of the Dangote refinery and Middle East bids as these are key catalysts for future growth.
JNK India Shareholders Approve Material Related Party Transactions; 36% Institutions Dissent
JNK India Limited has received shareholder approval for two material related party transactions (RPT) involving its subsidiary, JNK Chemdist Technologies. The resolutions passed with a 67.6% majority among voting public shareholders, as the promoter group abstained from voting due to being interested parties. While the resolutions were successful, a notable 36.4% of institutional votes were cast against the proposals. These transactions facilitate operational dealings between the parent, its subsidiary, and Chemdist Process Solutions.
முக்கிய அம்சங்கள்
Both resolutions for material related party transactions passed with a 67.62% majority.Public institutional participation was very high at 99.91%, though 36.40% of their votes were cast against the resolutions.Promoters and the promoter group, holding 37.9 million shares, did not participate in the voting as interested parties.The transactions involve JNK Chemdist Technologies Private Limited and Chemdist Process Solutions Private Limited.A total of 9.91 million votes were polled out of the eligible public shareholding base.
👀 கவனிக்க வேண்டியவை
Monitor future financial statements for the actual value and impact of these related party transactions on margins. The significant institutional dissent suggests investors should stay alert to corporate governance and arm's length pricing.
JNK India Q3 FY26 PAT Surges 534% YoY to ₹180.2 Mn; Order Book at ₹17,611 Mn
JNK India delivered a stellar performance in Q3 FY26, with revenue doubling to ₹2,062.3 Mn and PAT growing over six-fold to ₹180.2 Mn. The company's 9M FY26 revenue rose 67.2% YoY to ₹4,934.1 Mn, supported by a robust order book of ₹17,611 Mn which provides strong future visibility. EBITDA margins for the quarter improved significantly to 14.3% from 10.1% in the year-ago period. The company is successfully diversifying its portfolio with the commencement of operations at JNK Chemdist, focusing on sustainable fuels and chemicals.
முக்கிய அம்சங்கள்
Q3 FY26 Revenue grew 112.8% YoY to ₹2,062.3 Mn compared to ₹969.2 Mn in Q3 FY25.Q3 FY26 PAT skyrocketed 534.3% YoY to ₹180.2 Mn with PAT margins expanding to 8.7%.Total order book stands at ₹17,611 Mn as of December 31, 2025, with a 9M inflow of ₹11,372 Mn.Heating solutions remain the core segment, contributing 89.6% of the total order book.9M FY26 ROCE and ROE reported at 13.6% and 8.3% respectively.
👀 கவனிக்க வேண்டியவை
Investors should take note of the massive order book which is nearly 3.5x the 9M revenue, indicating strong growth potential. The significant margin expansion and successful entry into green energy segments through joint ventures make it a compelling growth story in the industrial equipment space.
JNK India Q3 FY26 Net Profit Surges to ₹184.6M; Revenue Up 92% YoY
JNK India reported a stellar performance for the quarter ended December 31, 2025, with standalone revenue from operations growing 91.7% YoY to ₹1,789.45 million. Net profit witnessed a massive jump to ₹184.58 million compared to just ₹29.10 million in the same quarter last year. For the nine-month period, the company's profit nearly doubled to ₹332.07 million from ₹168.78 million. The company also announced the operationalization of its new subsidiary, JNK Chemdist Technologies, marking an expansion into the process equipment segment.
முக்கிய அம்சங்கள்
Standalone Revenue from Operations grew 91.7% YoY to ₹1,789.45 million in Q3 FY26.Net Profit for the quarter skyrocketed to ₹184.58 million from ₹29.10 million in Q3 FY25.Basic EPS increased significantly to ₹3.30 in Q3 FY26 compared to ₹0.53 in the previous year's quarter.Nine-month revenue reached ₹4,560.83 million, a 60.6% increase over the ₹2,839.11 million recorded in 9M FY25.The company has successfully utilized ₹2,796.64 million of its IPO proceeds, primarily for working capital requirements.
👀 கவனிக்க வேண்டியவை
The company demonstrates robust growth in both top-line and bottom-line, reflecting strong execution in its core fired heaters business. Investors should monitor the scaling of the newly operationalized 'Process Equipment' segment as a potential future growth driver.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
